Last reviewed · How we verify

Givlaari — Competitive Intelligence Brief

Givlaari (GIVOSIRAN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminolevulinate Synthase 1-directed RNA Interaction. Area: Neuroscience.

marketed Aminolevulinate Synthase 1-directed RNA Interaction aminolevulinate synthase1 (ALAS1) mRNA Neuroscience Oligonucleotide Live · refreshed every 30 min

Target snapshot

Givlaari (GIVOSIRAN) — Alnylam Pharmaceuticals. Givlaari works by binding to and silencing the messenger RNA (mRNA) that produces the enzyme aminolevulinate synthase 1 (ALAS1), which is overproduced in patients with hepatic porphyria.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Givlaari TARGET GIVOSIRAN Alnylam Pharmaceuticals marketed Aminolevulinate Synthase 1-directed RNA Interaction aminolevulinate synthase1 (ALAS1) mRNA 2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminolevulinate Synthase 1-directed RNA Interaction class)

  1. Alnylam Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Givlaari — Competitive Intelligence Brief. https://druglandscape.com/ci/givosiran. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: